title: Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction.
abstract: 128 patients with acute myocardial infarction of duration 6 h or less were randomised in double-blind fashion to receive 30 U anistreplase over 5 min or 1.5 MU streptokinase over 1 h, both intravenously. Angiographic patency was assessed 90 min and 24 h from the start of therapy. 55% of patients who received anistreplase and 53% of patients who received streptokinase had patent infarct-related arteries (TIMI grade 2-3) at 90 min (95% CI 42-68% and 40-66%, respectively). At 24 h 81% and 87.5% of arteries were patent respectively (95% CI, 71-91% and 83.5-91.5%). Time to therapy had no significant effect on patency rates. There was one early reocclusion within 24 h in each treatment group and clinical evidence of reocclusion was recorded between 24 h and hospital discharge in a further 5 patients (streptokinase 3, anistreplase 2). With these regimens, therefore, anistreplase and streptokinase gave the same patency rates.
authors.affiliation: University Department of Medicine and Therapeutics, Stobhill General Hospital, Glasgow.
authors.forename: K J
authors.initials: KJ
authors.lastname: Hogg
authors.forename: J D
authors.initials: JD
authors.lastname: Gemmill
authors.forename: J M
authors.initials: JM
authors.lastname: Burns
authors.forename: W K
authors.initials: WK
authors.lastname: Lifson
authors.forename: A P
authors.initials: AP
authors.lastname: Rae
authors.forename: F G
authors.initials: FG
authors.lastname: Dunn
authors.forename: W S
authors.initials: WS
authors.lastname: Hillis
mesh_terms: D000328:Adult; D000368:Aged; D016255:Anistreplase; D001794:Blood Pressure / Q000187:drug effects; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D010958:Plasminogen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014654:Vascular Patency / Q000187:drug effects*
chemical_list: D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase